Dose de‐escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation
Alemtuzumab in vivo T-cell depletion is safe and effective at a single dose of 30 mg in reduced-intensity matched unrelated donor transplants.
Authors
- Jamie Macdonald
- Amy Publicover
- Callum Wright (ORCID: https://orcid.org/0000-0001-7997-9810)
- Sarah Pagan
- Jason Chun‐Ho Lam (ORCID: https://orcid.org/0000-0003-3085-1634)
- Paul Milne (ORCID: https://orcid.org/0000-0002-8278-0463)
- Venetia Bigley (ORCID: https://orcid.org/0000-0002-3017-2474)
- Maymoon Mohammed Madkhali (ORCID: https://orcid.org/0000-0002-9424-0966)
- Louise Duncan
- M. P. Collin
- Kim Pearce
- Alex Mitchell
- Geoffrey Hale
- Srishty Aku
Institutions
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- WheelRight (United Kingdom) (GB)
- Ministry of Health (KW)
- Newcastle University (GB)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1111/bjh.70318
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- NIHR Newcastle Biomedical Research Centre